Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Puntos clave
Ponatinib shows promise in improving progression-free survival in patients with metastatic gastrointestinal stromal tumor.
The trial indicated that ponatinib could be a viable option for patients intolerant to prior treatment with imatinib.
Phase II trial methodology was used to assess the effects of ponatinib on this specific patient population.
This trial's findings may highlight new treatment pathways for metastatic gastrointestinal stromal tumor patients.
Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial) | Synapse